Browsing Tag
Ryoncil
4 posts
Cats finally get a disease-modifying therapy candidate as Gallant pilot data clears the bar and FDA opens the fast lane
Gallant reports positive randomised trial data for feline osteoarthritis stem cell therapy and wins FDA expanded conditional approval eligibility. Read the full analysis.
Mesoblast (ASX: MSB) ramps up GVHD play with record Ryoncil revenue and fresh $125m credit line
Ryoncil sales surged 60 percent for Mesoblast in Q4. Read how its $125M refinancing plan could reshape capital efficiency and future cell therapy expansion.
FDA grants orphan drug exclusivity to Mesoblast’s Ryoncil for pediatric SR-aGvHD
Find out how Mesoblast's FDA approval for Ryoncil in pediatric SR-aGvHD sets a new benchmark in stem cell therapy and market exclusivity strategy.
Mesoblast issues shares to Osiris Therapeutics after FDA approval of Ryoncil
Mesoblast Limited, a pioneering biotechnology company listed on the Australian Securities Exchange (ASX:MSB), has announced the issuance of…